|
1
|
Smith RA, Cokkinides V, Brooks D, Saslow D
and Brawley OW: Cancer screening in the United States, 2010: A
review of current American Cancer Society guidelines and issues in
cancer screening. CA Cancer J Clin. 60:99–119. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
International Agency for Cancer Research,
. Estimated Incidence, Mortality and Prevalence Worldwide in 2012.
http://globocan.iarc.fr/old/FactSheets/cancers/breast-new.aspAccessed.
February 16–2016
|
|
3
|
Parkin DM and Fernández LM: Use of
statistics to assess the global burden of breast cancer. Breast J.
12(Suppl 1): S70–S80. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jankowitz RC, McGuire KP and Davidson NE:
Optimal systemic therapy for premenopausal women with hormone
receptor-positive breast cancer. Breast. 22(Suppl 2): S165–S170.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Montemurro F, Del Mastro L, De Laurentiis
M and Puglisi F: Endocrine therapy in premenopausal women with
breast cancer: A critical appraisal of current evidence. Expert Rev
Anticancer Ther. 16:211–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Howlader N, Chen VW, Ries LA, Loch MM, Lee
R, DeSantis C, Lin CC, Ruhl J and Cronin KA: Overview of breast
cancer collaborative stage data items - their definitions, quality,
usage, and clinical implications: A review of SEER data for
2004–2010. Cancer. 120(Suppl 23): 3771–3780. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hoskins JM, Carey LA and McLeod HL: CYP2D6
and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer.
9:576–586. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Motamedi S, Majidzadeh K, Mazaheri M,
Anbiaie R, Mortazavizadeh SM and Esmaeili R: Tamoxifen resistance
and CYP2D6 copy numbers in breast cancer patients. Asian Pac J
Cancer Prev. 13:6101–6104. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kiyotani K, Mushiroda T, Sasa M, Bando Y,
Sumitomo I, Hosono N, Kubo M, Nakamura Y and Zembutsu H: Impact of
CYP2D6*10 on recurrence-free survival in breast cancer patients
receiving adjuvant tamoxifen therapy. Cancer Sci. 99:995–999. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Morrow PK, Serna R, Broglio K, Pusztai L,
Nikoloff DM, Hillman GR, Fontecha M, Li R, Michaud L, Hortobagyi G,
et al: Effect of CYP2D6 polymorphisms on breast cancer recurrence.
Cancer. 118:1221–1227. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goetz MP, Knox SK, Suman VJ, Rae JM,
Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL,
et al: The impact of cytochrome P450 2D6 metabolism in women
receiving adjuvant tamoxifen. Breast Cancer Res Treat. 101:113–121.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van Schaik RH: Cancer treatment and
pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs.
23:513–522. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Martins DM, Vidal FC, Souza RD, Brusaca SA
and Brito LM: Determination of CYP2D6 *3, *4, and *10 frequency in
women with breast cancer in São Luís, Brazil, and its association
with prognostic factors and disease-free survival. Braz J Med Biol
Res. 47:1008–1015. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schroth W, Antoniadou L, Fritz P, Schwab
M, Muerdter T, Zanger UM, Simon W, Eichelbaum M and Brauch H:
Breast cancer treatment outcome with adjuvant tamoxifen relative to
patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 25:5187–5193.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Karle J, Bolbrinker J, Vogl S, Kreutz R,
Denkert C, Eucker J, Wischnewsky M, Possinger K and Regierer AC:
Influence of CYP2D6-genotype on tamoxifen efficacy in advanced
breast cancer. Breast Cancer Res Treat. 139:553–560. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
De la Vega FM, Lazaruk KD, Rhodes MD and
Wenz MH: Assessment of two flexible and compatible SNP genotyping
platforms: TaqMan SNP Genotyping Assays and the SNPlex Genotyping
System. Mutat Res. 573:111–135. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Abraham JE, Maranian MJ, Driver KE, Platte
R, Kalmyrzaev B, Baynes C, Luccarini C, Shah M, Ingle S, Greenberg
D, et al: CYP2D6 gene variants: Association with breast cancer
specific survival in a cohort of breast cancer patients from the
United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res.
12:R642010. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ingelman-Sundberg M: Genetic polymorphisms
of cytochrome P450 2D6 (CYP2D6): Clinical consequences,
evolutionary aspects and functional diversity. Pharmacogenomics J.
5:6–13. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fukuda T, Yamamoto I, Nishida Y, Zhou Q,
Ohno M, Takada K and Azuma J: Effect of the CYP2D6*10 genotype on
venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin
Pharmacol. 47:450–453. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Goetz MP, Kamal A and Ames MM: Tamoxifen
pharmacogenomics: The role of CYP2D6 as a predictor of drug
response. Clin Pharmacol Ther. 83:160–166. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Toyama T, Yamashita H, Sugiura H, Kondo N,
Iwase H and Fujii Y: No association between CYP2D6*10 genotype and
survival of node-negative Japanese breast cancer patients receiving
adjuvant tamoxifen treatment. Jpn J Clin Oncol. 39:651–656. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Irvin WJ Jr, Walko CM, Weck KE, Ibrahim
JG, Chiu WK, Dees EC, Moore SG, Olajide OA, Graham ML, Canale ST,
et al: Genotype-guided tamoxifen dosing increases active metabolite
exposure in women with reduced CYP2D6 metabolism: A multicenter
study. J Clin Oncol. 29:3232–3239. 2011. View Article : Google Scholar : PubMed/NCBI
|
